DVAX
Price
$10.06
Change
+$0.08 (+0.80%)
Updated
Sep 5 closing price
Capitalization
1.18B
53 days until earnings call
ESALF
Price
$32.32
Change
+$0.02 (+0.06%)
Updated
Sep 5 closing price
Capitalization
9.77B
Interact to see
Advertisement

DVAX vs ESALF

Header iconDVAX vs ESALF Comparison
Open Charts DVAX vs ESALFBanner chart's image
Dynavax Technologies
Price$10.06
Change+$0.08 (+0.80%)
Volume$1.42M
Capitalization1.18B
Eisai
Price$32.32
Change+$0.02 (+0.06%)
Volume$250
Capitalization9.77B
DVAX vs ESALF Comparison Chart in %
Loading...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DVAX vs. ESALF commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a Hold and ESALF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (DVAX: $10.06 vs. ESALF: $32.32)
Brand notoriety: DVAX and ESALF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: DVAX: 89% vs. ESALF: 9%
Market capitalization -- DVAX: $1.18B vs. ESALF: $9.77B
DVAX [@Pharmaceuticals: Generic] is valued at $1.18B. ESALF’s [@Pharmaceuticals: Generic] market capitalization is $9.77B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 0 FA rating(s) are green whileESALF’s FA Score has 2 green FA rating(s).

  • DVAX’s FA Score: 0 green, 5 red.
  • ESALF’s FA Score: 2 green, 3 red.
According to our system of comparison, ESALF is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 4 TA indicator(s) are bullish while ESALF’s TA Score has 7 bullish TA indicator(s).

  • DVAX’s TA Score: 4 bullish, 5 bearish.
  • ESALF’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, ESALF is a better buy in the short-term than DVAX.

Price Growth

DVAX (@Pharmaceuticals: Generic) experienced а -0.59% price change this week, while ESALF (@Pharmaceuticals: Generic) price change was +13.40% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

DVAX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ESALF($9.77B) has a higher market cap than DVAX($1.18B). DVAX has higher P/E ratio than ESALF: DVAX (54.60) vs ESALF (29.21). ESALF YTD gains are higher at: 25.808 vs. DVAX (-21.222). ESALF has higher annual earnings (EBITDA): 101B vs. DVAX (-34.26M). ESALF has more cash in the bank: 269B vs. DVAX (614M). DVAX has less debt than ESALF: DVAX (285M) vs ESALF (183B). ESALF has higher revenues than DVAX: ESALF (753B) vs DVAX (316M).
DVAXESALFDVAX / ESALF
Capitalization1.18B9.77B12%
EBITDA-34.26M101B-0%
Gain YTD-21.22225.808-82%
P/E Ratio54.6029.21187%
Revenue316M753B0%
Total Cash614M269B0%
Total Debt285M183B0%
FUNDAMENTALS RATINGS
DVAX vs ESALF: Fundamental Ratings
DVAX
ESALF
OUTLOOK RATING
1..100
6050
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
11
Undervalued
PROFIT vs RISK RATING
1..100
85100
SMR RATING
1..100
956
PRICE GROWTH RATING
1..100
8148
P/E GROWTH RATING
1..100
9791
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESALF's Valuation (11) in the null industry is somewhat better than the same rating for DVAX (69) in the Biotechnology industry. This means that ESALF’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's Profit vs Risk Rating (85) in the Biotechnology industry is in the same range as ESALF (100) in the null industry. This means that DVAX’s stock grew similarly to ESALF’s over the last 12 months.

ESALF's SMR Rating (6) in the null industry is significantly better than the same rating for DVAX (95) in the Biotechnology industry. This means that ESALF’s stock grew significantly faster than DVAX’s over the last 12 months.

ESALF's Price Growth Rating (48) in the null industry is somewhat better than the same rating for DVAX (81) in the Biotechnology industry. This means that ESALF’s stock grew somewhat faster than DVAX’s over the last 12 months.

ESALF's P/E Growth Rating (91) in the null industry is in the same range as DVAX (97) in the Biotechnology industry. This means that ESALF’s stock grew similarly to DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXESALF
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
54%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
36%
Momentum
ODDS (%)
Bearish Trend 3 days ago
74%
Bullish Trend 3 days ago
44%
MACD
ODDS (%)
Bearish Trend 5 days ago
69%
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
37%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 3 days ago
45%
Advances
ODDS (%)
Bullish Trend 26 days ago
75%
N/A
Declines
ODDS (%)
Bearish Trend 6 days ago
78%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
49%
Aroon
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 3 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DFE70.030.46
+0.65%
WisdomTree Europe SmallCap Dividend ETF
NMB24.630.09
+0.37%
Simplify National Muni Bond ETF
FLIA20.500.04
+0.22%
Franklin International Aggregate Bd ETF
JULZ45.10-0.13
-0.28%
Trueshares Structured Outcome July ETF
VONV88.44-0.28
-0.31%
Vanguard Russell 1000 Value ETF

DVAX and

Correlation & Price change

A.I.dvisor tells us that DVAX and BCRX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DVAX and BCRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+0.80%
BCRX - DVAX
32%
Poorly correlated
N/A
AMRX - DVAX
32%
Poorly correlated
+0.73%
ESPR - DVAX
32%
Poorly correlated
+5.93%
ALKS - DVAX
32%
Poorly correlated
+3.53%
SUPN - DVAX
29%
Poorly correlated
+1.25%
More

ESALF and

Correlation & Price change

A.I.dvisor tells us that ESALF and ESAIY have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESALF and ESAIY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESALF
1D Price
Change %
ESALF100%
+0.06%
ESAIY - ESALF
30%
Poorly correlated
+2.66%
KHTRF - ESALF
27%
Poorly correlated
N/A
DVAX - ESALF
22%
Poorly correlated
+0.80%
BLMH - ESALF
20%
Poorly correlated
-1.59%
DBCCF - ESALF
15%
Poorly correlated
-3.24%
More